Holding(s) in Company

RNS Number : 9534R
Advanced Oncotherapy PLC
10 November 2021
 

 

TR-1: Standard form for notification of major holdings

 

 

1a. Identity of the issuer or the underlying issuerof existing shares to which voting rights are at-tache ii :

 

AdvancedOncotherapyPlc

1b.Pleaseindicateifthe issuerisa non-UKissuer (pleasemarkwithan "X"ifappropriate)

Non-UKissuer

 

2.Reasonforthenotification (pleasemarktheappropriatebox orboxeswithan"X")

Anacquisitionordisposal ofvotingrights

 

Anacquisitionordisposaloffinancialinstruments

 

Aneventchangingthebreakdownofvoting rights

X

Other(pleasespecify)  iii :

 

3. Detailsofpersonsubjecttothenotificationobligation  iv

Name

CelesteManagement SA

Cityandcountryofregisteredoffice(ifapplicable)

Geneva,Switzerland

4. Fullnameofshareholder(s) (ifdifferentfrom3.) v

Cityandcountryofregisteredoffice(ifapplicable)

 

5. Date on which the threshold was crossed orreached vi :

24thSeptember2021

6.Dateonwhichissuernotified(DD/MM/YYYY):

9th November2021

7.Totalpositionsofperson(s)subjecttothe notificationobligation

 

% of voting rights at-tachedtoshares(to-talof8.A)

% of voting rightsthroughfinancialinstru-ments

(totalof8.B 1+8.B2)

 

Totalofbothin%(8.A+8.B)

Total number ofvotingrightsheldin issuer(8.A+

8.B) vii

Resulting situationonthedateonwhichthreshold wascrossedorreached

 

6.29%

 

 

6.29%

 

28,333,333

Positionofpreviousnotification(ifapplicable)

 

8.50%

 

 

8.50%

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed orreached  viii

A:Votingrights attached toshares

Class/type ofshares

ISINcode(ifpossible)

Numberof votingrights  ix

%ofvotingrights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

 

28,333,333

 

6.29%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL8.A

28,333,333

6.29%

 

B1:FinancialInstrumentsaccordingto DTR5.3.1R(1)(a)

 

Typeoffinancialin-strument

 

Expirationdate  x

 

Exercise/ConversionPeriod  xi

Numberofvotingrightsthat may be acquired iftheinstrument is

exercised/converted.

 

%of votingrights

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL8.B1

 

 

 

B2: FinancialInstrumentswithsimilar economiceffectaccordingto DTR5.3.1R(1)(b)

Typeoffinancialinstrument

Expirationdate  x

Exercise/Conversion Pe-riod  xi

Physical orcashSettlement  xii

Number ofvotingrights

 

%of votingrights

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

                   

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark theapplicableboxwith an"X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does notcontrolanyotherundertaking(s)holdingdirectlyorindirectlyan interestin the(underlying)issuer xiii

X

Full chainofcontrolledundertakingsthroughwhichthe votingrightsand/orthe

financialinstrumentsareeffectivelyheldstartingwiththeultimatecontrollingnaturalpersonor legalentity(please addadditionalrowsas necessary)  xiv

 

 

 

Name  xv

% of voting rights if itequals or is higherthan the notifiablethreshold

% of voting rightsthrough financial in-strumentsifitequals

or is higher than thenotifiablethreshold

Total of both if itequals or is higherthan the notifiablethreshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. Incase of proxyvoting,pleaseidentify:

Name oftheproxyholder

 

Thenumber and%ofvotingrights held

 

Thedateuntilwhichthevotingrightswillbe held

 

 

11.Additionalinformation xiv

 

         

 

Placeofcompletion

Geneva

Date ofcompletion

9thNovember2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLURORRAUUAAAA
UK 100

Latest directors dealings